Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
JSPR Analyst Ratings
Moderate Buy
4 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
JSPR Stock 12 Month Forecast
Average Price Target
$9.25
▲(422.60% Upside)
| Highest Price Target$20.00 | Average Price Target$9.25 | Lowest Price Target$4.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
RBC Capital
$4
Hold
125.99%
Upside
Reiterated
12/02/25
H.C. Wainwright
$20
Buy
1029.94%
Upside
Reiterated
12/02/25
Jasper Therapeutics: Strategic Patient Selection and Consistent Drug Performance Justify Buy RatingValuation and Risks. Our Buy rating and $20 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2040 and assign a 12% discount rate and no terminal value. We currently assume value for briquilimab for the treatment of CSU with 50% POS and and have not included other pipeline assets or indications in our valuation.
BTIG
$7
Buy
295.48%
Upside
Reiterated
12/02/25
William Blair
―
Hold
―
Reiterated
12/02/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jasper Therapeutics (NASDAQ: JSPR) and Azitra Inc (NYSE MKT: AZTR)We believe this profile would be at least competitive with and potentially differentiated from Celldex’s barzolvolimab, which showed a 51% complete response rate at week 12 (versus 6% with placebo) in Phase II.Beyond the CSU investigation update, we view the early asthma data as quite intriguing, showing improvements in both FEV1 reductions and methacholine-induced hyperresponsiveness 6 and 12 weeks after a single treatment with briquilimab. The early asthma results must be cautioned by the small patient numbers and only single-dose nature of the study, but we believe repeating this efficacy in a larger study would support development of briquilimab in asthma patients and offer longer-term upside to the addressable total addressable market (TAM) opportunity for KIT inhibition.
TD Cowen
―
Buy
―
Reiterated
11/10/25
Citizens JMP
$12→$6
Buy
238.98%
Upside
Reiterated
09/22/25
UBS
$29→$25
Buy
1312.43%
Upside
Reiterated
08/15/25
Evercore ISI
$50→$20
Buy
1029.94%
Upside
Reiterated
07/08/25
Cantor Fitzgerald
―
Hold
―
Downgraded
07/07/25
Oppenheimer
$65
Buy
3572.32%
Upside
Reiterated
06/16/25
Truist Financial
$48→$46
Buy
2498.87%
Upside
Reiterated
05/12/25
Wells Fargo
$80
Buy
4419.77%
Upside
Reiterated
03/02/25
Barclays
$63
Buy
3459.32%
Upside
Initiated
02/27/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
RBC Capital
$4
Hold
125.99%
Upside
Reiterated
12/02/25
H.C. Wainwright
$20
Buy
1029.94%
Upside
Reiterated
12/02/25
Jasper Therapeutics: Strategic Patient Selection and Consistent Drug Performance Justify Buy RatingValuation and Risks. Our Buy rating and $20 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2040 and assign a 12% discount rate and no terminal value. We currently assume value for briquilimab for the treatment of CSU with 50% POS and and have not included other pipeline assets or indications in our valuation.
BTIG
$7
Buy
295.48%
Upside
Reiterated
12/02/25
William Blair
―
Hold
―
Reiterated
12/02/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jasper Therapeutics (NASDAQ: JSPR) and Azitra Inc (NYSE MKT: AZTR)We believe this profile would be at least competitive with and potentially differentiated from Celldex’s barzolvolimab, which showed a 51% complete response rate at week 12 (versus 6% with placebo) in Phase II.Beyond the CSU investigation update, we view the early asthma data as quite intriguing, showing improvements in both FEV1 reductions and methacholine-induced hyperresponsiveness 6 and 12 weeks after a single treatment with briquilimab. The early asthma results must be cautioned by the small patient numbers and only single-dose nature of the study, but we believe repeating this efficacy in a larger study would support development of briquilimab in asthma patients and offer longer-term upside to the addressable total addressable market (TAM) opportunity for KIT inhibition.
TD Cowen
―
Buy
―
Reiterated
11/10/25
Citizens JMP
$12→$6
Buy
238.98%
Upside
Reiterated
09/22/25
UBS
$29→$25
Buy
1312.43%
Upside
Reiterated
08/15/25
Evercore ISI
$50→$20
Buy
1029.94%
Upside
Reiterated
07/08/25
Cantor Fitzgerald
―
Hold
―
Downgraded
07/07/25
Oppenheimer
$65
Buy
3572.32%
Upside
Reiterated
06/16/25
Truist Financial
$48→$46
Buy
2498.87%
Upside
Reiterated
05/12/25
Wells Fargo
$80
Buy
4419.77%
Upside
Reiterated
03/02/25
Barclays
$63
Buy
3459.32%
Upside
Initiated
02/27/25
Best Analysts Covering Jasper Therapeutics
1 Month
xxx
Success Rate
8/15 ratings generated profit
Average Return
-2.02%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of -2.02% per trade.
3 Months
xxx
Success Rate
6/15 ratings generated profit
Average Return
+2.83%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +2.83% per trade.
1 Year
Success Rate
2/13 ratings generated profit
Average Return
-55.00%
reiterated a buy rating 14 days ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -55.00% per trade.
2 Years
xxx
Success Rate
2/13 ratings generated profit
Average Return
-56.35%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 15.38% of your transactions generating a profit, with an average return of -56.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
JSPR Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Nov 25
Dec 25
Strong Buy
15
14
13
9
7
Buy
4
3
2
2
1
Hold
4
6
7
5
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
23
22
16
13
Each month's total comprises the sum of three months' worth of ratings.
JSPR Financial Forecast
JSPR Stock Forecast FAQ
What is JSPR’s average 12-month price target, according to analysts?
Based on analyst ratings, Jasper Therapeutics’s 12-month average price target is 9.25.
What is JSPR’s upside potential, based on the analysts’ average price target?
Jasper Therapeutics has 422.60% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is JSPR a Buy, Sell or Hold?
Jasper Therapeutics has a consensus rating of Moderate Buy which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.
What is Jasper Therapeutics’s price target?
The average price target for Jasper Therapeutics is 9.25. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $4.00. The average price target represents 422.60% Increase from the current price of $1.77.
The highest analyst price target is $20.00 ,the lowest forecast is $4.00. The average price target represents 422.60% Increase from the current price of $1.77.
What do analysts say about Jasper Therapeutics?
Jasper Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of JSPR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.